Malignant Melanoma As Second Malignant Neoplasm in Long-term Childhood Cancer Survivors: a Systematic Review
Overview
Oncology
Pediatrics
Authors
Affiliations
This systematic review provides information on malignant melanoma as second malignant neoplasm (SMN) after childhood cancer and evaluates its risk factors. Study reports describing incidences of SMN and malignant melanoma as SMN in a population of childhood cancer survivors (CCS) were included. Of 151,575 CCS, 4,010 (2.6%) children developed an SMN, 212 of which were melanoma (5.3% or 0.14% of all CCS). The following risk factors for malignant melanoma as SMN were identified: radiotherapy, or the combination alkylating agents and anti-mitotic drugs. Melanomas are most frequently observed after Hodgkin disease, hereditary retinoblastoma, soft tissue sarcoma, and gonadal tumors.
Malignant melanoma in a 12-year-old boy 17 months after completing hepatoblastoma treatment.
Kanezawa K, Yagasaki H, Arakawa A, Hoshi R, Uehara S, Morioka I Cancer Rep (Hoboken). 2024; 7(5):e2118.
PMID: 38801212 PMC: 11129619. DOI: 10.1002/cnr2.2118.
Cutaneous Melanoma and Glioblastoma Multiforme Association-Case Presentation and Literature Review.
Orzan O, Giurcaneanu C, Dima B, Dima M, Ion A, Balaceanu B Diagnostics (Basel). 2023; 13(6).
PMID: 36980355 PMC: 10047677. DOI: 10.3390/diagnostics13061046.
Zeng C, Chen T, Wang J, Sun F, Huang J, Lu S Cancer Med. 2023; 12(8):9409-9419.
PMID: 36808251 PMC: 10166922. DOI: 10.1002/cam4.5703.
Peil J, Bock F, Kiefer F, Schmidt R, Heindl L, Cursiefen C Int J Mol Sci. 2022; 23(3).
PMID: 35163401 PMC: 8835854. DOI: 10.3390/ijms23031478.
Geller A, Keske R, Haneuse S, Davine J, Emmons K, Daniel C J Invest Dermatol. 2019; 139(9):1898-1905.e2.
PMID: 30959042 PMC: 6708770. DOI: 10.1016/j.jid.2019.02.033.